Diabetes is a condition that has many variables. Researchers are finding more and more about how genetics and patient behavior play a role; however, it turns out that socioeconomic status, education, and ethnic background all play a role as well.
On Monday afternoon, Jessica Robbins, PhD, member of the Philadelphia Department of Public Health and Adjunct Professor at Drexel, presented on the role of socioeconomic status in diabetes risk and outcomes. The overarching framework used for this discussion was the social ecological framework. Dr. Robbins presented alarming data regarding the disparity of diabetes prevalence both in terms of racial background and socioeconomic status. Here are some of the general observations that Dr. Robbins presented along with references to both local and national studies:
- The African American population continues to show more susceptibility to diabetes than non-Hispanic whites, and this pattern is consistent across many studies
- Household income is an excellent predictor of diabetes prevalence; households with $50,000/year in income had half as much a rate of incidence (5%) as those which have $35,000/year (10%)
- Exploring Health Disparities in Integrated Communities (EHDIC) Study found that whites and African Americans in integrated communities had similar odds of having diabetes, despite substantial racial/ethnic disparities at the population level
- Diabetes disparities are greater in women than men, both in terms of racial background and socioeconomic status
- Disparities decline by age, especially among the very old, although this may reflect measuring issues
- Some studies have found that those who go to college have the lowest risk of contracting diabetes, both in racial and gender groups
- The DISTANCE cohort study (Kaiser Permanente Southern California) found disparities in glycemic control and other intermediate clinical outcomes were associated with the socioeconomic status of patients’ area of residence
Although there have been numerous studies conducted to analyze the various factors that are associated with diabetes, there still remains widespread debate as to which factors are more revealing than others, especially when considering that many of these factors are interrelated. However, Dr. Robbins concluded by saying that the effects of socioeconomic status on diabetes outcomes are without question “big, not inevitable, and unacceptable.”
For more information on this session, please visit the American Diabetes Association’s website.
Social Epidemiology of Diabetes
Diabetes is a condition that has many variables. Researchers are finding more and more about how genetics and patient behavior play a role; however, it turns out that socioeconomic status, education, and ethnic background all play a role as well.
Diabetes is a condition that has many variables. Researchers are finding more and more about how genetics and patient behavior play a role; however, it turns out that socioeconomic status, education, and ethnic background all play a role as well.
On Monday afternoon, Jessica Robbins, PhD, member of the Philadelphia Department of Public Health and Adjunct Professor at Drexel, presented on the role of socioeconomic status in diabetes risk and outcomes. The overarching framework used for this discussion was the social ecological framework. Dr. Robbins presented alarming data regarding the disparity of diabetes prevalence both in terms of racial background and socioeconomic status. Here are some of the general observations that Dr. Robbins presented along with references to both local and national studies:
Although there have been numerous studies conducted to analyze the various factors that are associated with diabetes, there still remains widespread debate as to which factors are more revealing than others, especially when considering that many of these factors are interrelated. However, Dr. Robbins concluded by saying that the effects of socioeconomic status on diabetes outcomes are without question “big, not inevitable, and unacceptable.”
For more information on this session, please visit the American Diabetes Association’s website.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Exploring Care Needs, Physical Activity in Myotonic Dystrophy
March 19th 2025Posters presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference highlight the complex care needs and physical activity barriers for individuals with myotonic dystrophy.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Trump Administration Cancels Crucial Funding for Diabetes Prevention Program
March 18th 2025Recent cuts to federal grants are set to have a widespread impact across numerous scientific and medical studies.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Exploring Care Needs, Physical Activity in Myotonic Dystrophy
March 19th 2025Posters presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference highlight the complex care needs and physical activity barriers for individuals with myotonic dystrophy.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Trump Administration Cancels Crucial Funding for Diabetes Prevention Program
March 18th 2025Recent cuts to federal grants are set to have a widespread impact across numerous scientific and medical studies.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More